UroGen Pharma (URGN) Insider Arie Belldegrun Buys 20,000 Shares
On June 22, Arie Belldegrun purchased 20,000 shares of URGN.
Reviewed by automated data checks against the source filing. How we make and check alerts
Arie Belldegrun bought 20,000 shares of UroGen Pharma Ltd. ($URGN) on June 22, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $URGN is up 3.1% after 1 week, up 20.2% after 1 month and down 1.2% to date (from the $34.99 close on Jun 22, 2026).
URGN
UroGen Pharma Ltd.
Key Points
- Arie Belldegrun bought 20,000 shares of URGN on June 22, 2026, with shares trading near $35.8.
- URGN's stock saw activity from several institutional investors, including BlackRock, Inc. and Toronto Dominion Bank.
- Analysts like HC Wainwright & Co. and Oppenheimer maintain buy ratings on URGN with targets up to $45.
Get $URGN trade alerts by text
We text you when insiders, Congress or big funds trade $URGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated UroGen Pharma Ltd. alert may contain errors. Disclosures
Arie Belldegrun, a noted insider, purchased 20,000 shares of URGN on June 22, 2026. The transaction was not planned in advance and occurred as the company's shares traded near $35.8.
Other Institutional Activity in URGN
Institutional investors have also been active in URGN's stock. BlackRock, Inc. increased its holdings by 244,558 shares, bringing its total to 2,845,567 shares valued at approximately $51.2 million, marking a 9.4% increase. Toronto Dominion Bank opened a new position with 2,616,714 shares worth about $47 million. Meanwhile, Morgan Stanley slightly reduced its stake by 2,863 shares, ending with 2,560,038 shares valued at $46 million. Kynam Capital Management, LP also initiated a new position, holding 2,247,393 shares valued at around $40.4 million.
UroGen Pharma Ltd. Stock Down 17.7%
As of Wednesday, URGN shares were trading near $35.8. The company has seen various institutional movements, reflecting interest in its potential. Analysts have maintained positive ratings, suggesting confidence in its future performance.
Insider Buying and Selling at UroGen Pharma Ltd.
On June 22, 2026, several insiders, including Robinson James Jr., Leana Wen, and Cynthia Butitta, also bought shares of URGN. Robinson James Jr. acquired a total of 18,000 shares, while Leana Wen and Cynthia Butitta each bought 10,000 shares. These transactions were not part of any pre-planned trading programs.
Analysts Set New Price Targets
Analysts continue to show optimism for URGN. On May 11, 2026, HC Wainwright & Co. maintained a buy rating with a $45 price target. Oppenheimer also upheld its buy rating with a $40 target on May 7, 2026. Overall, the consensus remains positive, with a strong buy recommendation and an average target price reflecting potential growth.
Bottom Line
Arie Belldegrun's recent purchase of URGN shares highlights insider confidence in the company's prospects. Institutional activity further underscores this interest, with both new positions and increased holdings reported. Analysts echo this sentiment with maintained buy ratings and robust price targets, suggesting continued optimism in URGN's future performance.
Related Filing Alerts
Source: Arie Belldegrun's Form 4 filing on $URGN (Jun 22, 2026). Find the original filing: URGN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts